Prostate cancer is the second most occurring cancer in men worldwide. To better
understand the mechanisms of tumorigenesis and possible treatment responses, we …

Mechanistic modeling of signaling pathways mediating patient‐specific response to therapy
can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating …

Inter and intra-tumoral heterogeneity are major stumbling blocks in the treatment of cancer
and are responsible for imparting differential drug responses in cancer patients. Recently …

Although genetically engineered mouse (GEM) models are often used to evaluate cancer
therapies, extrapolation of such preclinical data to human cancer can be challenging. Here …

Making decisions on how best to treat cancer patients requires the integration of different
data sets, including genomic profiles, tumour histopathology, radiological images, proteomic …

Background Androgen deprivation therapy is a first-line treatment for disseminated prostate
cancer (PCa). However, virtually all tumors become resistant and recur as castration …

Mechanistic models are essential to deepen the understanding of complex diseases at the
molecular level. Nowadays, high-throughput molecular and phenotypic characterizations …

Recent advances in pharmacogenomics have generated a wealth of data of different types
whose analysis have helped in the identification of signatures of different cellular …

Immunotherapy, by enhancing the endogenous anti-tumor immune responses, is showing
promising results for the treatment of numerous cancers refractory to conventional therapies …

Background Genome-scale metabolic models (GEMs) offer insights into cancer metabolism
and have been used to identify potential biomarkers and drug targets. Drug repositioning is …